The Concept of Developing a Plasmodium vivax Malarial Vaccine with a Focus on its Pre-erythrocytic Stage
DOI:
https://doi.org/10.17140/VROJ-3-109Keywords:
Plasmodium vivax, Parasites, Relapses, Immunoprophylaxis, Circumsporozoite protein, Vaccine development, Immune responses, Pre-erythrocytic stage vaccineAbstract
Plasmodium vivax, one of the most prevalent human malarial parasites, continues to cause significant morbidity for hundreds of
millions worldwide. Due to increasing drug resistance and vivax specific relapses, immunoprophylaxis signifies a key control strategy
in efforts to eradicate malaria worldwide. By far, the circumsporozoite protein (CSP) based vaccines are being developed since the
1980’s. However, they have produced major limitations in eliciting partial immune responses towards the parasite. Nevertheless,
the Long Synthetic Peptides (LSP’s) and Vivax Malarial Protein 001 (VMP001) have produced considerable amount of immune
responses and are currently undergoing phase 1 clinical trials according to several studies. Recent developments of a Virus-like
particle (VLP) was found to be an efficacious vaccine candidate against a human sporozoite challenge model. The VLP’s elicited
high antibody titers that remained consistent for a number of days but eventually decreased. In addition, vaccine candidates such
as the VLP’s are currently being used to target CSP based–antigens such as the Cell-Traversal Proteins to obstruct hepatocyte
invasion by sporozoites. However, substantial humoral and cellular immune responses were not produced to alleviate this process.
Further research of these vaccine candidates as well as to analyze its effects towards specific CSP based antigens would immensely
contribute to move clinical development forward and to further identify mechanism of immunity.
References
Herrera S, Corradin G, Arévalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends in Parasitology. 23(3): 122-128. 2007. doi: 10.1016/j.pt.2007.01.008
Corradin G, Céspedes N, Verdini A, Kajava A, Arévalo-Herrera M. et al. Malaria vaccine development using synthetic peptides as a technical platform. Synthetic Vaccines. 107-149. 2012. doi: 10.1016/B978-0-12-396548-6.00005-6
Lumsden J, Nurmukhambetova S, Klein J, Sattabongkot J, Ben-nett J, et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combi-nation with second-generation adjuvants in mice, Vaccine, 30(22): 3311-3319. 2012. doi: 10.1016/j.vaccine.2012.03.004
Lai S, Li Z, Wardrop N, Sun J, Head M., et al. Malaria in China, 2011–2015: An observational study. Bull World Health Organ. 95(8): 564-573. 2017. doi: 10.2471/BLT.17.191668
World Health Organization (WHO) (2018) World malaria re-port, Website. http://www.who.int/malaria/publications/world_ malaria_report/en/. Accessed December 12 2017.
Cornejo O, Escalante A. The origin and age of Plasmodium vivax. Trends in Parasitology. 22(12): 558-563. 2006. doi: 10.1016/j. pt.2006.09.007
Baer K, Klotz C, Kappe S, Schnieder T, Frevert U. Release of hepatic Plasmodium yoelii merozoites into the pulmonary micro-vasculature. PLoS Pathogens. 3(11): 171. 2007. doi: 10.1371/journal. ppat.0030171
Lima-Junior J, Pratt-Riccio L. Major histocompatibility complex and malaria: Focus on Plasmodium vivax infection. Front Immunol. 7. 2016. doi: 10.3389/fimmu.2016.00013 Review | Volume 3 | Number 1| Dias S
Reyes-Sandoval A, Khan S, Janse C, Bachmann M, Hill A. De-velopment of a Plasmodium vivax malaria vaccine for clinical applications using transgenic parasites, virus-like particles and re-combinant viruses. Malar J. 13: 77. 2014. doi: 10.1186/1475-2875- 13-S1-P77
Chuangchaiya S, Jangpatarapongsa K., Chootong P, Sirichaisin-thop J, Sattabongkot J, et al. Immune response to Plasmodium vivax has a potential to reduce malaria severity. Clinical & Ex-perimental Immunology. 160(2): 233-239. 2009. doi: 10.1111/j.1365- 2249.2009.04075.x
Jangpatarapongsa K, Xia H, Fang Q, Hu K., Yuan Y, et al. Immunity to malaria in Plasmodium vivax infection: A Study in Central China. PLoS ONE. 7(9). 2012. doi: 10.1371/journal. pone.0045971
Reyes-Sandoval A, Bachmann M. Plasmodium vivax malaria vaccines: Why are we where we are?. Hum Vaccin Immunother. 9(12): 2558-2565. 2013. doi: 10.4161/hv.26157
Good M, Kaslow D, Miller L. Pathways and strategies for de-veloping a malaria blood-stage vaccine. Annu Rev Immunol. 16(1): 57-87. 1998. doi: 10.1146/annurev.immunol.16.1.57
Bennett J, Yadava A, Tosh D, Sattabongkot J, Komisar J, et al. Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity and efficacy. PLOS Neglected Tropical Diseases. 10(2): 4423. 2016. doi: 10.1371/journal.pntd.0004423
Collins W, Chulay J, Barr P, Ruebush T, Bathurst I, et al. Im-munization of Saimiri Sciureus Boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium Vivax. Am J Trop Med Hyg. 40(5): 455-464. 1989. doi: 10.4269/ ajtmh.1989.40.455
Herrington D, Bathurst I, Losonsky G, Hollingdale M, Levine M, et al. Safety and immunogenicity of a recombinant sporozo-ite malaria vaccine against Plasmodium vivax. Am J Trop Med Hyg. 45(6): 695-701. 1991. doi: 10.1016/0264-410X(92)90047-N
Herrera S, Corradin G, Velez J, Soto L, Fernandez O, et al. Safety and elicitation of humoral and cellular responses in colum-bian malaria-naïve volunteers by a Plasmodium Vivax cicumsporo-zoite protein-derived synthetic vaccine. Am J Trop Med Hyg. 73: 3-9. 2005. doi: 10.4269/ajtmh.2005.73.3
Arévalo-Herrera M, Castellanos A, Céspedes N, Soto L, Cor-radin G, et al. Preclinical vaccine study of Plasmodium vivax cir-cumsporozoite protein derived-synthetic polypeptides formulated in Montanide ISA 720 and Montanide ISA 51 adjuvants. Am J Trop Med Hyg. 84: 21-27. 2011. doi: 10.4269/ajtmh.2011.10-0110
Gnjatic S, Sawhney N, Bhardwaj N. Toll-Like Recep-tor Agonists. The Cancer Journal. 16(4): 382-391. doi: 10.1097/ PPO.0b013e3181eaca65
Yadava A, Hall C, Sullivan J, Nace D, Williams T, et al. Pro-tective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae Is associated with antibodies to the repeat region, PLoS Neglected Tropical Diseases, 8(10): .e3268. 2014. doi: 10.1371/journal.pntd.0003268
Souza-Neiras W, Melo L, Machado R. The genetic diversity of Plasmodium vivax: a review. Mem Inst Oswaldo Cruz. 102(3): 245- 254. 2007. DOI: 10.1590/S0074-02762007000300002
Salman A, Montoya-Díaz E, West H, Lall A, Atcheson E, et al. Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Sci Rep. 7: 46482. 2017. doi: 10.1038/srep46482
Alves E, Salman A, Leoratti F, Lopez-Camacho C, Viveros-Sandoval, et al. Evaluation of Plasmodium vivax cell-traversal pro-tein for ookinetes and sporozoites as a pre-erythrocytic P. vivax vaccine. Clinical and Vaccine Immunology. 24(4): 1-16. 2017. doi: Submit your article to this journal | https://openventio.org/submit-manuscript/ 10.1128/cvi.00501-16
Bitencourt Chaves L, Perce-da-Silva D, Rodrigues-da-Silva R., Martins da Silva J, Cassiano G, et al. Plasmodium vivax cell tra-versal protein for ookinetes and sporozoites (PvCelTOS) gene se-quence and potential epitopes are highly conserved among isolates from different regions of Brazilian amazon. PLOS Neglected Tropical Diseases. 11(2). 2017. doi: 10.1371/journal.pntd.0005344
Akache B, Weeratna R, Deora A, Thorn J, Champion, et al. Anti-IgE Qb-VLP conjugate vaccine self-adjuvants through ac-tivation of TLR7. Vaccines. 4(1): p.3. 2016. doi: 10.1371/journal. pntd.0005344
Rodrigues-da-Silva R., Soares I, Lopez-Camacho C, Martins da Silva J, Perce-da-Silva D, et al. Plasmodium vivax cell-traversal pro-tein for ookinetes and sporozoites: naturally acquired humoral im-mune response and b-cell epitope mapping in Brazilian amazon in-habitants. Front Immunol. 8. 2017. doi: 10.3389/fimmu.2017.00077
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
